hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06376734 id: 2024p000528 briefTitle: Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness acronym: Searchlight overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2029-06-01 date: 2030-06-01 date: 2024-04-19 date: 2024-04-19 name: Brigham and Women's Hospital class: OTHER name: National Institutes of Health (NIH) briefSummary: Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits. conditions: Major Depressive Disorder conditions: Obsessive-Compulsive Disorder conditions: Schizophrenia conditions: Generalized Anxiety Disorder conditions: Mood Disorders conditions: Psychiatric Disorder conditions: Mental Disorder conditions: Depression, Anxiety studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Double-blind, randomized controlled crossover trial. Participants will be stimulated at a random location in the prefrontal cortex, which will be mapped to its underlying brain network to determine which network was stimulated. primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: All participants will receive real open-label TMS, so there will be no conventional masking. However, participants and investigators will be blinded to which network is being stimulated. count: 180 type: ESTIMATED name: TMS measure: Clustering of multiple behavioral measures sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376721 id: TREC2024-KY016 briefTitle: Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma overallStatus: RECRUITING date: 2024-04-14 date: 2026-10-31 date: 2027-10-31 date: 2024-04-19 date: 2024-04-19 name: Beijing Tongren Hospital class: OTHER briefSummary: The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment. conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type conditions: T-lymphoblastic Lymphoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Treatment with linperlisib in combination with camrelizumab and pegaspargase for advanced or relapsed/refractory ENKTCL patients primaryPurpose: TREATMENT masking: NONE count: 43 type: ESTIMATED name: Linperlisib name: Camrelizumab name: Pegaspargase name: Dexamethasone measure: The best objective response rate（ORR） over 6 treatment cycles measure: Objective Response Rate（ORR） measure: Complete Response （CR） measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: Disease Control Rate（DCR） measure: Drug safety sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Liang Wang status: RECRUITING city: Beijing state: Beijing country: China name: Liang Wang, M.D. role: CONTACT phone: +8615001108693 email: wangliangtrhos@126.com name: Liang Wang, M.D. role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06376708 id: 3-3-13 briefTitle: Comparison Between PEEK With Platelet-rich Fibrin and PEEK Alone in Maxillary Sinus Augmentation overallStatus: COMPLETED date: 2022-09-01 date: 2023-03-01 date: 2023-07-01 date: 2024-04-19 date: 2024-04-19 name: Cairo University class: OTHER briefSummary: comparison between the resulted bone during maxillary sinus elevation by PEEK with and without platelet rich fibrin conditions: Maxillary Sinus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: use of platelet rich fibrin after maxillary sinus elevation using PEEK primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 24 type: ACTUAL name: platelet rich fibrin name: Polyether ether ketone measure: Bone quantity measure: Bone quality sex: ALL minimumAge: 20 Years maximumAge: 50 Years stdAges: ADULT facility: Faculty of Dentistry Cairo University city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06376695 id: RADX-P-2407 briefTitle: Radicle GI Health 24: A Study of Health and Wellness Products on GI Health and Related Health Outcomes overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-19 date: 2024-06 date: 2024-10 date: 2024-04-19 date: 2024-04-23 name: Radicle Science class: INDUSTRY briefSummary: A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on GI health and related health outcomes conditions: Abdominal Pain conditions: GI Disorders conditions: Digestion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be stratified based on gender at birth then randomized to one of the study arms primaryPurpose: OTHER masking: DOUBLE maskingDescription: The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 500 type: ACTUAL name: Radicle GI Health Placebo Control Form 1 name: Radicle GI Health Active Study Product 1.1 Usage measure: Change in GI (Gastrointestinal) Health (1) measure: Change in GI (Gastrointestinal) Health (2) measure: Change in GI (Gastrointestinal) Health (3) measure: Change in GI (Gastrointestinal) Health (4) measure: Change in GI (Gastrointestinal) Health (5) measure: Change in GI (Gastrointestinal) Health (6) measure: Change in feelings of anxiety measure: Change in GI-related Quality of Life (QOL) measure: Change in mood (emotional distress-depression) measure: Minimal clinically important difference (MCID) in GI Health (1) measure: Minimal clinically important difference (MCID) in GI Health (2) measure: Minimal clinically important difference (MCID) in GI Health (3) measure: Minimal clinically important difference (MCID) in GI Health (4) measure: Minimal clinically important difference (MCID) in GI Health (5) measure: Minimal clinically important difference (MCID) in GI Health (6) measure: Minimal clinically important difference (MCID) in feelings of anxiety measure: Minimal clinically important difference (MCID) in GI-related QOL measure: Minimal clinically important difference (MCID) in mood (emotional distress-depression) measure: Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool sex: ALL minimumAge: 21 Years maximumAge: 105 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Radicle Science, Inc city: Del Mar state: California zip: 92014 country: United States lat: 32.95949 lon: -117.26531 hasResults: False
nctId: NCT06376682 id: CA-BO-CIP-0060 briefTitle: EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy acronym: EPIBONE overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2024-12-31 date: 2025-02-28 date: 2024-04-19 date: 2024-04-19 name: Quantum Surgical class: INDUSTRY briefSummary: Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for bone percutaneous procedures. conditions: Bone Metastases conditions: Fractures, Bone conditions: Bone Tumor studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The Epione device is an image-guided robotized device that assists the physician during CT-guided procedures. primaryPurpose: TREATMENT masking: NONE count: 33 type: ESTIMATED name: CT-guided bone percutaneous procedure measure: Successful instrument insertion with the EPIONE device. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376669 id: J2421 id: IRB00427823 type: OTHER domain: JHM IRB briefTitle: Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma acronym: SPARE overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-06 date: 2030-08 date: 2024-04-19 date: 2024-04-19 name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins class: OTHER briefSummary: This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival. conditions: Renal Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Proton Stereotactic Body Radiation therapy (SBRT) measure: Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels measure: Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) values measure: Number of PROTON-BASED SBRT treatment Adverse Events measure: Local progression of disease after PROTON-BASED SBRT treatment as assessed by size or appearance of lesions measure: Systemic progression of disease after PROTON-BASED SBRT treatment as assessed by appearance of lesions measure: Time to locoregional progression measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376656 id: LRGS/1/2019/SYUC/02/1 briefTitle: Successful Aging and Age-related Decline acronym: MyAgeWell overallStatus: RECRUITING date: 2022-05-20 date: 2029-05 date: 2030-05 date: 2024-04-19 date: 2024-04-19 name: Sunway University class: OTHER briefSummary: Recent studies have shown promising cognitive and physical interventions aimed at slowing down ageing-related declines in quality of life, but they lack strong ecological validity (brief durations, unrealistic goals, no real-world application) and has yet to show robust evidence that such interventions are stable and suitable in the long-term. The investigators aim to examine whether these interventions can, over four years, significantly slow down the normal rate of ageing-related decline. conditions: Aging conditions: Elderly conditions: Cognitive Decline conditions: Physical Decline conditions: Intervention Study studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A cohort of older Malaysian adults will be recruited and assigned to one of the groups, either cognitive stimulation, physical activity, combined cognitive stimulation and physical activity, or non-intervention control. primaryPurpose: PREVENTION masking: NONE count: 400 type: ESTIMATED name: Cognitive stimulation name: Physical activity measure: Changes in cognitive scores measure: Changes in electroencephalogram (EEG) measure: Changes in structural magnetic resonance imaging (MRI) measure: Cost-benefit analysis of intervention measure: Changes in levels of human salivary lactoferrin measure: Changes in levels of human salivary C-reactive proteins measure: Changes in salivary telomere length measure: Changes in depression scores measure: Changes in anxiety scores sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sunway University status: RECRUITING city: Petaling Jaya state: Selangor zip: 47500 country: Malaysia name: Michael J Jenkins, PhD role: CONTACT phone: +60374918622 phoneExt: 7183 email: michaeljj@sunway.edu.my lat: 3.10726 lon: 101.60671 hasResults: False
nctId: NCT06376630 id: 298-2024 briefTitle: Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI acronym: ESMO-VASCMI overallStatus: RECRUITING date: 2024-01-29 date: 2029-01-29 date: 2030-01-29 date: 2024-04-19 date: 2024-04-19 name: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation class: OTHER_GOV briefSummary: Study rationale: to evaluate clinical and prognostic relevance of microvascular dysfunction, coronary flow reserve and cardioprotective effects of iv administration of esmolol in patients with myocardial infarction.
First substudy is an open randomized trial evaluating the efficacy and safety of early intravenous administration of esmolol in patients with acute ST-segment elevation myocardial infarction (MI) and relative contraindications to administration of other intravenous β1-adrenergic blocker (metoprolol etс.). Сomparison group will include patients who have not received intravenous β1-adrenergic blocker. Secondary outcome in this substudy is the degree of microvascular obstruction and infarct size according to MRI with gadolinium delayed enhancement.
Second substudy examines the quantitative parameters of coronary physiology in patients with MI and multivessel disease. Changes of coronary physiology measurements over time ((iFR, Pd/Pa, FFR, delta FFR, gradient FFR per time unit (dFFR(t)/dt), pullback pressure gradient (PPG)) measured in the infarct-related artery and in non-infarct-related arteries with diameter stenosis of 50-85% immediately after the completion of a primary percutaneous coronary intervention and during a second hospitalization (30-45 days after STEMI) will be evaluated. The comparison changes of coronary physiology over time with presence of an MVO and infarct size determined by MRI. The model of calculating coronary flow reserve (CFR) based on tridimensional reconstruction of coronary arteries and coronary physiology parameters as measured during coronary angiography will be developed. The influence of coronary physiology parameters measured after complete myocardial revascularization by PCI, and derived CFR in patients with MI on long-term clinical outcomes will be evaluated, based on prospective data collection.
Secondary composite outcome in all substudies is the degree of microvascular obstruction and infarct size evaluated by MRI with gadolinium delayed enhancement. conditions: Myocardial Infarction conditions: Coronary Stenosis conditions: Coronary Microvascular Dysfunction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 300 pts with MI are to be enrolled. Among them 100 pts with STEMI will be included into the substudy evaluating cardioprotective effects of early iv administration of esmolol. They will be randomized 1:1 by in arms receiving esmolol or no IV beta-blockers. In the esmolol arm the infusion will begin immediately on admission. 200 pts with MI and multivessel disease with non-IRA lesions of 50-85% diameter stenosis will be included into another substudy investigating coronary physiology. All patients will undergo PCI with IRA stenting. 50 stable patients will undergo invasive measurements of coronary physiology. Those will also undergo cardiac MRI. Other 150 pts will not undergo invasive measurements of coronary physiology during initial hospitalization. Pts in both groups will be hospitalized again in 30-40 days after MI. They will undergo stress SPECT or stress echocardiography. All patients will undergo a follow-up coronary angiography with invasive measurement of coronary physiology. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: envelopes whoMasked: INVESTIGATOR count: 300 type: ESTIMATED name: Esmolol Hcl 10Mg/Ml Inj measure: Composite of adverse cardiac outcomes measure: Degree of microvascular obstruction measure: Infarct size sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NMRCCardiologyRu status: RECRUITING city: Moscow country: Russian Federation name: Andrey Komarov, PhD role: SUB_INVESTIGATOR name: Tatiana Sukhinina, PhD role: SUB_INVESTIGATOR name: Mariy Terenicheva, PhD role: SUB_INVESTIGATOR name: Olga Stukalova, PhD role: SUB_INVESTIGATOR name: Sergey Ternovoy, Academic role: SUB_INVESTIGATOR name: Goar Arutiunian, PhD role: SUB_INVESTIGATOR name: Evgeniy Merkulov, PhD role: SUB_INVESTIGATOR name: Viktor Shitov, MD role: SUB_INVESTIGATOR name: Marina Saidova, PhD role: SUB_INVESTIGATOR name: Aleksey Ansheles, PhD role: SUB_INVESTIGATOR name: Vladimir Sergienko, PhD role: SUB_INVESTIGATOR lat: 55.75222 lon: 37.61556 hasResults: False
nctId: NCT06376617 id: MS.24.03.2743 briefTitle: Pattern Of Isolated Fungi From Bronchoalveolar Lavage Among Patients With Bronchial Asthma overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2025-04-20 date: 2025-05-20 date: 2024-04-19 date: 2024-04-19 name: Mansoura University class: OTHER briefSummary: This study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma conditions: Bronchial Asthma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar. primaryPurpose: DIAGNOSTIC masking: NONE count: 60 type: ESTIMATED name: fibroptic bronchoscopy measure: assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06376604 id: LNT55 briefTitle: Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies overallStatus: RECRUITING date: 2021-09-08 date: 2025-09-01 date: 2025-12-30 date: 2024-04-19 date: 2024-04-19 name: L-Nutra Inc class: INDUSTRY name: University of Tennessee Medical Center briefSummary: This study evaluates how lifestyle modifications that may be made to manage chemotherapy side effects in patients with gynecologic malignancies. conditions: Cancer, Ovarian conditions: Chemotherapy Effect conditions: Calorie Deficiency conditions: Fasting, Intermittent studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: Outcomes Assessor count: 30 type: ESTIMATED name: Fasting Mimicking Diet name: Chemotherapy measure: Quality of life by National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index (NFOSI-18) questionnaire measure: Rate of Adherence measure: Change in Body Weight measure: Change in Body Composition measure: Change in HbA1c measure: Change in Insulin Like Growth Factor 1 (IGF-1) Concentration measure: Change in Fasting Insulin Concentration measure: Change in Fasting Glucose Concentration measure: Change in High-sensitivity C reactive protein Concentration measure: Change in Leptin Concentration measure: Change in planned chemotherapy regimen measure: Number of Hospitalization Days measure: Rate of Chemotherapy Side Effects sex: FEMALE minimumAge: 35 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The University of Tennessee Medical Center status: RECRUITING city: Knoxville state: Tennessee zip: 37920 country: United States name: Jonathan D Boone, MD role: CONTACT phone: 865-305-5622 email: jboone@utmck.edu lat: 35.96064 lon: -83.92074 hasResults: False
nctId: NCT06376591 id: LUMHS/B12/Temp/12.04.2024 briefTitle: Assessing the Efficacy of Different Carrier Systems in Oral Vitamin B12 Supplementation in Healthy Adults With B12 Deficiency overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2024-07-31 date: 2024-08-31 date: 2024-04-19 date: 2024-04-19 name: Liaquat University of Medical & Health Sciences class: OTHER briefSummary: Vitamin B12, a vital nutrient, plays a crucial role in red blood cell formation, neurological function, and DNA synthesis. Deficiency in B12 can lead to anemia, neurological symptoms such as tingling or numbness, and cognitive impairment. Oral B12 supplementation serves as an effective strategy to address B12 deficiency, especially for individuals with limited dietary intake or absorption issues. Regular B12 supplementation can help restore body B12 levels, alleviate deficiency-related symptoms, and support overall health and well-being. conditions: Vitamin B 12 Deficiency studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Oral Vitamin B12 supplement name: Control group measure: Supplementation effect on circulatory vitamin B12 levels measure: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) measure: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) measure: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Liaquat University of Medical and Health Sciences city: Jamshoro zip: 76090 country: Pakistan name: Dr. Ikram Ujjan, MBBS, PhD role: CONTACT phone: 03000506955 email: ikramujjan@lumhs.edu.pk lat: 25.43773 lon: 68.28522 hasResults: False
nctId: NCT06376578 id: 245256 briefTitle: Exercise Interventions for Improving Health in Breast Cancer Survivors overallStatus: COMPLETED date: 2018-09-05 date: 2020-01-30 date: 2020-01-30 date: 2024-04-19 date: 2024-04-19 name: University of Bath class: OTHER briefSummary: Supervised, prescribed exercise has positive effects on body composition, physical functioning, psychological wellbeing and quality of life for patients after breast cancer treatment. However, exercise interventions are often time consuming, commonly take place at a health or fitness facility, and usually require a trained professional to be present. Cost-effective, enjoyable and practical approaches, that can be adopted at home or in local surroundings are needed. For example, an alternative approach is using an electronic physical activity tracking wristwatch to help patients engage with exercise or physical activity. Research demonstrates the importance of structured and supervised exercise for breast cancer survivors. However, it is not known whether other approaches (e.g. home-based exercise and physical activity) alongside the use of personalised technology-enabled feedback, can cause similar improvements to health when compared to structured exercise. The overall aim of this study is to determine whether cardiorespiratory fitness is changed by a technology enabled, remotely delivered exercise intervention and to determine whether this change is similar to the change caused by a partly supervised, prescribed exercise intervention. This study will also determine the influence of both interventions on physical functioning, body composition and blood pressure. conditions: Breast Cancer Female studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ACTUAL name: Exercise intervention name: Polar A380 wristwatch physical activity tracker measure: Change in VO2max (maximum oxygen uptake) measure: Change in Body composition measure: Change in physical functioning measure: Change in Psychological measures measure: Change in immune profiles and function sex: FEMALE minimumAge: 35 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Bath city: Bath zip: BA2 7AY country: United Kingdom lat: 51.3751 lon: -2.36172 hasResults: False